On August 31, PHARMARON fell 3.33% in regular trading, trading at 28.38 HKD/share, with turnover of HK$34.71 million. The decline was driven by continued market concerns over share dilution from the company's proposed convertible bond issuance, compounded by a significant share transfer and sector-wide selling pressure.

On August 26, PHARMARON entered into a subscription agreement to issue RMB 2.18 billion in zero-coupon USD-settled convertible bonds due August 2027, with an initial conversion price of HK$36.08 per H share. If fully converted, approximately 70.48 million new H shares would be issued, representing 3.70% of the enlarged total share capital. The board formally approved the proposal on August 27. Meanwhile, on August 28, a position transfer of 16.24 million shares worth approximately HK$541 million was moved out of HSBC, accounting for 4.98% of shares, further intensifying cautious sentiment.

The broader CXO sector was under significant pressure, with Insilico Medicine down 5.62%, WuXi Biologics down 4.84%, GenScript Biotech down 4.45%, WuXi XDC down 3.61%, and WuXi AppTec down 3.40%, reflecting widespread industry-linked selling.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)